Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00481520 | Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease | PHASE2 | COMPLETED | 72 | — | — | Jun 1, 2007 | Jan 1, 2008 | Sep 30, 2009 | 7 | United States |
| NCT00906191 | Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects | PHASE1 | COMPLETED | 6 | — | — | May 1, 2009 | Aug 1, 2009 | Aug 26, 2009 | 1 | Netherlands |
| NCT00745576 | Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered | PHASE1 | COMPLETED | 14 | — | — | Oct 1, 2008 | Dec 1, 2008 | Feb 8, 2010 | 1 | France |
| NCT00726115 | Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531 | PHASE1 | COMPLETED | 56 | — | — | Aug 1, 2008 | Feb 1, 2009 | Jul 30, 2009 | 1 | France |
| NCT00479349 | Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 | PHASE1 | COMPLETED | 32 | — | — | May 1, 2007 | Jan 1, 2008 | Jul 7, 2009 | 1 | Japan |
| NCT00480818 | Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects | PHASE1 | COMPLETED | 80 | — | — | Sep 1, 2006 | Jul 1, 2007 | Dec 11, 2007 | 1 | France |
| NCT00479297 | Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males | PHASE1 | COMPLETED | 72 | — | — | May 1, 2006 | Feb 1, 2007 | Aug 7, 2009 | - | — |
| NCT00479700 | Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects | PHASE1 | COMPLETED | 80 | — | — | May 1, 2006 | Jul 1, 2006 | Dec 10, 2007 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SAM-531 | DRUG | - |
| placebo | OTHER | - |
Inclusion Criteria 1. Signed and dated written informed consent obtained from the subject or the subject's legally authorized representative (LAR) or next of kin (if applicable), in accordance with the local regulations. The subject's caregiver must also consent to participate in the study. 2. Diag...